Please login to the form below
anti-CD3 mAb
This page shows the latest anti-CD3 mAb news and features for those working in and with pharma, biotech and healthcare.
Tiziana to develop intranasal foralumab for type 1 diabetes
Gabriele Cerrone, executive chairman, founder and interim chief executive officer of Tiziana, said: “With the FDA approval of the humanised anti-CD3 mAb Tzield and then its subsequent announced acquisition of ... Although given intranasal, our fully
Latest news
-
Tiziana completes enrolment of first patient cohort in MS expanded access programme
Foralumab, the only entirely human anti-CD3 mAb, has also shown reduced release of cytokines after intravenous administration in healthy volunteers and in patients with Crohn's disease. ... thereby providing therapeutic benefit in treating inflammatory
-
Tiziana starts enrolment in secondary progressive MS expanded access programme
Foralumab, the only entirely human anti-CD3 mAb, has also shown reduced release of cytokines after intravenous administration in healthy volunteers and in patients with Crohn's disease. ... thereby providing therapeutic benefit in treating inflammatory
-
Tiziana’s Foralumab shows promise in second patient with secondary progressive MS
date. Foralumab, the only entirely human anti-CD3 mAb, has shown reduced release of cytokines after intravenous administration in healthy volunteers and in patients with Crohn's disease. ... thereby providing therapeutic benefit in treating inflammatory
-
Tiziana announces Brigham and Women’s hospital will receive ALS Association grant
The research follows the company's recently presented positive findings on intranasal anti-CD3 mAb in Alzheimer’s disease preclinical models of neuroinflammation. ... study the role of intranasal anti-CD3 mAb in dampening the microglial activation
-
Tiziana joins type 1 diabetes prevention field
Teplizumab is a mouse derived anti-CD3 mAb, and is administered intravenously. ... Now Tiziana is looking to rival Provention with the development of its own anti-CD3 mAB foralumab, which it says is the only entirely human anti-CD3 mAb.
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Latest appointments
-
Dr Kunwar Shailubhai appointed CEO of Tiziana Life Sciences
Shailubhai takes the helm as Tiziana focuses on developing an orally administered, anti-CD3 mAb (foalumab) drug candidate to manage non-alcoholic steatohepatitis (NASH) - a liver disease that has no treatment
More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Contagious Conversations: Exploring Infectious Disease in the Digital Age
- Austrian State Secretary to speak at FlyPharma Europe 2023
- Further data for AstraZeneca/Daichii Sankyo’s Enhertu for breast cancer requested by NICE
- Gritstone Bio receives $433m BARDA contract for COVID-19 vaccine candidate
- EDX Medical Group develops multi-disease 'point-of-care' rapid tests for cancer, infections and cardiovascular conditions
- ScreenPoint Medical to showcase AI software at European scientific meeting
No results were found
PMHub
AMICULUM
AMICULUM® is an independent global healthcare communications, consulting and learning business with a global team of >300 healthcare communications professionals,...
Latest intelligence
- The importance of accelerating clinical trial diversity
- Diversity shouldn’t be an afterthought – it’s an investment in the credibility of scientific endeavour...
- Digital Opinion Leaders: The Role of Influencers in Medical Communications
- There are many informed, knowledgeable HCPs who talk about a disease state online, but not all of them are influencers. This paper explores who digital opinion leaders are and how...
- Creating Hope Though Action – World Suicide Prevention Day
- At Mednet Group, we believe that actions speak louder than words. That's why we're getting behind this year's Suicide Prevention Day campaign of 'creating hope through action'....
